tiprankstipranks
Trending News
More News >
Medical Developments International Limited (AU:MVP)
ASX:MVP

Medical Developments International Limited (MVP) AI Stock Analysis

Compare
8 Followers

Top Page

AU

Medical Developments International Limited

(Sydney:MVP)

Rating:44Neutral
Price Target:
Medical Developments International Limited has a low overall stock score due to significant financial challenges. Persistent losses and negative profit margins highlight operational inefficiencies. The technical analysis provides mixed indicators, with some short-term upward momentum but potential overbought conditions. Valuation remains a concern with a negative P/E ratio and no dividend yield, reflecting profitability and risk issues.

Medical Developments International Limited (MVP) vs. iShares MSCI Australia ETF (EWA)

Medical Developments International Limited Business Overview & Revenue Model

Company DescriptionMedical Developments International Limited (MVP) is a leading healthcare company specializing in innovative medical solutions across various sectors, including pain management, respiratory products, and veterinary equipment. The company is well-known for its flagship product, Penthrox, a fast-acting inhaled analgesic used for pain relief in emergency situations. Additionally, MVP develops and manufactures a range of medical devices and equipment aimed at improving patient care and outcomes.
How the Company Makes MoneyMVP generates revenue primarily through the sale of its medical products, particularly Penthrox, which has a strong presence in multiple international markets. The company also earns income from its respiratory and veterinary product lines, which include asthma devices and veterinary anaesthetic equipment. Key revenue streams involve direct product sales to healthcare providers, hospitals, and distributors. Significant partnerships with international pharmaceutical companies and distributors help expand its market reach and sales potential. Furthermore, MVP invests in research and development to enhance its product offerings and maintain its competitive edge in the medical industry.

Medical Developments International Limited Financial Statement Overview

Summary
Medical Developments International Limited faces significant financial challenges across all financial statements. The income statement reveals persistent losses and negative profit margins, indicating operational inefficiencies. While the balance sheet shows low leverage, the negative return on equity reflects profitability struggles. The cash flow statement highlights liquidity issues with negative operating and free cash flows. The company must address cost management and improve operational efficiency to achieve financial stability.
Income Statement
28
Negative
The company's income statement reveals a concerning trend, with declining revenue and significant losses in recent years. The gross profit margin has been negative in past years, indicating cost management issues. Despite a slight revenue increase in 2024, net profit margins remain deeply negative. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Overall, the income statement reflects financial instability and a challenging path to profitability.
Balance Sheet
45
Neutral
The balance sheet shows a moderate debt-to-equity ratio, reflecting relatively low leverage, which provides some stability. However, the return on equity is negative due to consistent net losses. The equity ratio is reasonably strong, suggesting a solid base of equity relative to assets, but the trend of declining equity over recent years is concerning. Overall, the balance sheet shows some strengths in terms of low debt levels, but the negative equity returns highlight profitability issues.
Cash Flow
32
Negative
The cash flow statement indicates significant challenges, with negative operating and free cash flows consistently. The operating cash flow to net income ratio suggests poor cash conversion, and the free cash flow to net income ratio is also negative, highlighting cash flow inadequacies. While there was an improvement in free cash flow in 2024, the overall cash flow situation remains weak, pointing to liquidity concerns and reliance on external financing.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
38.05M33.15M32.34M21.94M25.27M22.54M
Gross Profit
17.67M24.37M-2.52M-3.06M16.67M13.74M
EBIT
-1.17M-16.87M-20.27M-15.70M-5.24M1.87M
EBITDA
-15.53M-29.45M-4.28M-12.86M-11.11M3.03M
Net Income Common Stockholders
-29.74M-40.99M-5.61M-12.41M-12.56M379.00K
Balance SheetCash, Cash Equivalents and Short-Term Investments
2.13M9.73M24.66M20.40M36.28M15.54M
Total Assets
19.10M59.16M109.49M101.36M100.17M94.85M
Total Debt
0.002.29M2.56M2.81M3.05M3.36M
Net Debt
-2.13M-7.45M-22.10M-17.59M-33.23M-12.19M
Total Liabilities
1.52M13.43M28.17M44.06M31.87M51.51M
Stockholders Equity
16.64M45.73M81.31M57.30M68.30M43.34M
Cash FlowFree Cash Flow
-6.79M-13.95M-24.16M-15.94M-15.37M-8.30M
Operating Cash Flow
-5.08M-10.78M-16.50M-10.72M-8.81M601.00K
Investing Cash Flow
-2.06M-3.17M-7.67M-5.21M-6.56M-8.90M
Financing Cash Flow
8.69M-807.00K28.06M142.00K36.12M-1.97M

Medical Developments International Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.62
Price Trends
50DMA
0.56
Positive
100DMA
0.60
Positive
200DMA
0.52
Positive
Market Momentum
MACD
0.01
Positive
RSI
52.98
Neutral
STOCH
30.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:MVP, the sentiment is Positive. The current price of 0.62 is above the 20-day moving average (MA) of 0.61, above the 50-day MA of 0.56, and above the 200-day MA of 0.52, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 52.98 is Neutral, neither overbought nor oversold. The STOCH value of 30.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:MVP.

Medical Developments International Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AURMD
79
Outperform
AU$56.78B27.9325.23%0.85%10.54%38.69%
AUCOH
73
Outperform
$17.56B47.4520.61%1.61%6.35%5.97%
AUSHL
72
Outperform
AU$12.68B23.176.86%4.05%10.15%6.20%
AUCSL
69
Neutral
$117.14B28.1215.38%1.85%8.00%9.09%
AURHC
66
Neutral
$8.65B1,057.580.52%2.23%7.25%-99.04%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
AUMVP
44
Neutral
AU$69.85M-45.40%13.61%-55.12%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:MVP
Medical Developments International Limited
0.62
0.22
55.00%
AU:CSL
CSL
241.92
-40.08
-14.21%
AU:RHC
Ramsay Health Care
37.65
-9.99
-20.97%
AU:COH
Cochlear
268.49
-52.84
-16.44%
AU:SHL
Sonic Healthcare Limited
26.39
2.49
10.42%
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
38.23
6.84
21.79%

Medical Developments International Limited Corporate Events

Medical Developments International Issues New Performance Rights
Jun 2, 2025

Medical Developments International Limited announced the issuance of 2,687,635 performance rights under an employee incentive scheme. These securities are unquoted and subject to transfer restrictions, reflecting the company’s strategy to incentivize its workforce and align their interests with corporate performance, potentially impacting its operational efficiency and market positioning.

The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.

Medical Developments International Appoints New Director to Drive Strategic Growth
May 30, 2025

Medical Developments International Limited announced the resignation of Richard Betts and the appointment of Paul Townsend to its Board, effective 30 May 2025. Paul Townsend, a seasoned finance leader with extensive experience across multiple sectors, will assume the role of Chair of the Audit & Risk Committee. His background in driving business outcomes and leading major organizational changes is expected to support MVP’s strategic growth objectives. The company anticipates that Townsend’s expertise will aid in unlocking its full potential and achieving long-term global growth.

The most recent analyst rating on (AU:MVP) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Medical Developments International Limited stock, see the AU:MVP Stock Forecast page.

Medical Developments International Reports Strong Q3 FY25 Performance
Apr 29, 2025

Medical Developments International Limited reported strong financial performance for Q3 FY25, with a $1.7 million operating cash flow and a cash balance of $19.1 million. The company saw increased demand for Penthrox in both the Australian hospital segment and European markets, signing a new distribution agreement with Ethypharm in France. Despite expected lower earnings in the second half of FY25 due to foreign exchange rates, the company anticipates improved full-year EBIT driven by higher Penthrox prices and operational efficiencies.

Medical Developments International Appoints New Director
Apr 1, 2025

Medical Developments International Limited has announced the appointment of Mark Fladrich as a director effective April 1, 2025. The announcement, made under listing rule 3.19A.1, indicates that there are currently no relevant interests in securities or contracts associated with the new director, which suggests a straightforward transition without immediate financial implications for the company.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.